Report Date: 2026-11-15|Scope: Weight-loss and metabolic drugs targeting GLP-1 and extended targets (GIP/GCG/amylin/oral small molecules)—covering oral and injectable formulations, competitive target landscape, payment systems and commercial-scale capacity
This industry comprises weight-loss and metabolic therapies centered on GLP-1 receptor agonism and extending into multi-target and oral formulations, including: ① GLP-1R single-target peptides (semaglutide injectable/oral, liraglutide and its biosimilars); ② GLP-1/GIP dual agonists (tirzepatide, VK2735, HRS-9531, BGM0504); ③ GLP-1/GCG dual agonists (mazdutide, survodutide); ④ GLP-1/GIP/GCG triple agonists (retatrutide, HDM1005); ⑤ amylin analogs and fixed combinations with GLP-1 (CagriSema, petrelintide, eloralintide); ⑥ oral small-molecule GLP-1R agonists (orforglipron/Foundayo, HDM1002, etc.). The indication boundary covers chronic weight management, type 2 diabetes (T2DM), and comorbidity expansion (cardiovascular risk, OSA, MASH, CKD, HFpEF).
One-sentence value-chain map: Molecule design (patents and clinical evidence) → Peptide/small-molecule API (Novo's Kalundborg, Lilly's self-built Lebanon sites + Bachem/WuXi and other CDMOs) → Sterile fill-finish (Catalent's three plants acquired by Novo; Lilly self-built) → Delivery devices (injection pens/auto-injectors) → Payment (US commercial insurance/PBM/Medicare/Medicaid, China medical insurance + out-of-pocket, European public payers) → Patients. This report leads with pipeline delivery and catalysts (an R&D-driven industry), with demand, capacity, payment, and competitive landscape as supporting sections.
The global obese population is roughly 1.1 billion (WHO 2024); overweight-plus-obese adults number 402 million in China and 172 million in the US (GBD 2025); diabetes patients number 589 million, 43% of them undiagnosed (IDF 11th edition). Penetration is still at floor levels: GLP-1 prescription penetration among the US "obesity + diabetes" population is about 6% (Morgan Stanley anchor, 2025); adult self-reported current use is 11–12% (Gallup 2026/KFF); China's penetration is below 0.1% (Reuters 2026-10); India and Brazil are below 0.2%. Three S-curves of structural expansion: penetration ramp (MS baseline: ~30% in the US by 2035, ~10% elsewhere), indication expansion (repricing "weight-loss drugs" as a chronic-disease platform), and oral formulations cutting out-of-pocket thresholds from a monthly cash price of $349–499 to $149–299.
2025 base year: global GLP-1 (obesity + T2DM) net sales of roughly $79 billion (Morgan Stanley citing actuals; company financials cross-check at ~$76–80 billion), with roughly 39 million treated patients. 2030 estimate: $131.6 billion, a 11.0% CAGR:
| Driver | Increment | Core assumptions |
|---|---|---|
| US volume growth | +$12.1bn | Penetration 6%→11% (within MS trajectory interpolation), patients 8.28M→15.18M; blended net price $5,500→$3,800/patient-year (blend of Medicare $245/month, oral cash price, commercial net price) |
| Ex-US volume growth | +$33.4bn | Penetration 2%→3.7%, patients 31.0M→57.4M; semaglutide patent expiring from 2026 in markets covering 38% of obese adults globally (IQVIA); China/India domestic drug ramp |
| New indications | +$8.0bn | MASH (Wegovy approved 2025-08), OSA (Zepbound 2024-12), CKD (Ozempic 2025-01), CV risk (Wegovy 2024-03) conservatively at 1–3% specialty penetration |
| Total net increase | +$53.5bn | = 131.6 − 78.1, arithmetically consistent |
Cross-validation with institutional ranges: IQVIA forecasts $92 billion in 2026 and a $105–200 billion range from 2027; Goldman Sachs $95 billion for 2030 (a 2025-05 downward revision assuming heavier price erosion); TD $139 billion; JPMorgan $200 billion for 2030; Morgan Stanley $190 billion for 2035. Our bridge deviates +7.4% from MS's implied 2030 path (~$122.5 billion) and -5.3% from TD's—cross-validation passed; GS's path serves as the bear-case lower bound (see I7).
In 2025, oral accounted for only ~4.3% of revenue (Rybelsus ~$3.4bn). The inflection came in 2026: oral Wegovy (25mg semaglutide tablet) launched in the US on 2026-01-05, capturing roughly one-third of new-category prescriptions within 8 weeks, surpassing 3 million cumulative prescriptions by 2026-06, and posting $354 million in sales in 2026Q1; Lilly's orforglipron (Foundayo, the first oral small molecule) received FDA approval on 2026-04-01 (national priority voucher pathway, approved 50 days after submission) and was approved in China on 2026-11-12. Key quantitative facts: the oral cash price of $149–299/month is 40–57% of the injectable cash price ($349–499), and roughly 39% below the government-negotiated price of $245; per IQVIA's actual measurement, two-thirds of oral users had never used any GLP-1 before—oral is market expansion, not stock conversion. Gabelli projects oral at roughly one-third of the market by 2030 (our bridge: ~25–33% revenue share, higher volume share). The efficacy trade-off: orforglipron delivered 12.4% weight loss at 72 weeks (ATTAIN-1) vs ~20% for injectable dual agonists, but with no food/water restrictions, room-temperature storage, and access to primary-care channels.
Real-world 1-year retention is only 32–55% (definition-sensitive): Epic dual-criteria cohort shows a 53.6% 1-year discontinuation rate (Rodriguez 2025); Truveta/ADA 2026 shows 55% of new obesity users discontinuing at 12 months (semaglutide 57% vs tirzepatide 43%); well-reimbursed Nordic T2DM cohorts retain 75–80%, while high-out-of-pocket markets fall below 10%. Post-discontinuation weight regain and reinitiation are common—the revenue model is essentially "first year contributes most of the revenue + low-price maintenance-dose refills"; our bridge already discounts the active stock by ~0.5–0.65 patient-years. Warning signal: the US commercial insurance side is clearing out—Massachusetts official data show commercial GLP-1 weight-loss users down 112,000 YoY in 2026Q1 (-52%), and net prices for weight-loss GLP-1s fell 43% from 2019 to early 2026; employer surveys show 67% coverage but only 72% explicitly committed to renewing in 2027. Rising prescription penetration does not mean proportionate revenue growth—this is the demand bridge's single largest sensitivity.
Tirzepatide (2024-12-19) and semaglutide (2025-02-21) were sequentially removed from the FDA shortage list, closing the compounding exemption window; the FDA set Import Alert 66-80 "green list" in 2025-09 and in 2026-02 cut off Chinese API channels for compounders, ending the "shortage arbitrage" model. As of 2026-11, branded supply is ample; Novo raised full-year guidance on 2026-11-04 and is accelerating oral Wegovy rollout.
Branded players run a vertically closed "API–fill-finish–device" loop: Novo's Kalundborg expansion ~$6bn (one of only two semaglutide API sites globally), the $11bn Catalent three-plant acquisition (in use immediately upon closing 2024-12), the new Clayton fill-finish plant $4.1bn (2027–2029), Chartres France ~$2.3bn; Lilly's Lebanon, Indiana campus $9bn plus an added $4.5bn (tirzepatide API; first plant online 2026-05), four new plants totaling $27bn (Richmond/Houston/Huntsville etc., breaking ground 2026 through phased startup by 2030). China CDMO side: WuXi AppTec's Taixing peptide solid-phase reactor capacity exceeds 100,000 liters (largest in China, completed early in 2025-09); Asymchem 45,000→69,000 liters (end-2026); Hansoh/Hybio Wuhan new 10-ton/year project (announced 2026-10).
The tightest link is now not capacity but regulatory access: the FDA green list keeps Chinese peptide APIs out of US compounding channels (tightening continuously since 2025-09); Chinese manufacturers' mitigation is completing DMF registrations one by one (a Chinese semaglutide API made the list as of 2026-09), with pacing determined by FDA review rather than capex. The next-tightest link is new sterile fill-finish capacity (Clayton 2027–2029, Houston 2029+), but oral substitution on the demand side is easing rather than worsening that bottleneck; injection pens are clearly loosening—Gerresheimer cut guidance in 2025-06 citing "soft demand."
Capital signals have turned: Novo's capex peaked at DKK 60.1bn in 2025 and is ~DKK 50bn in 2026 (-16.8%), with official statements that it will keep declining over coming years, plus 9,000 layoffs in 2025-09—yet simultaneously announced a tenfold expansion plan for oral GLP-1 capacity (2026-09 CMD), a capital reallocation from "grabbing all capacity" to "oral ↑ injectable ↓"; Lilly is still doubling down. Oversupply pressure ranking: China's generic-grade peptide API (WuXi TIDES backlog growth has fallen from +103.9% to +20.2%, while industry capacity is released in concentration) > injection devices > independent fill-finish CDMOs > branded self-built capacity. Offsets: patent cliffs from 2026 in Canada/India/China/Brazil (covering ~44% of the global population) drive generic API demand, and the US $245/month payment price stimulates volume. Oralization (orforglipron relies on conventional small-molecule capacity, with no fill-finish/device dependency) is structural erosion for the injectable chain, not a cyclical fluctuation.
Key readouts and filings over the next 12–18 months will determine the 2028–2030 landscape:
| Asset | Company | Mechanism | Stage | Key data | Next catalyst |
|---|---|---|---|---|---|
| Tirzepatide | Lilly | GLP-1/GIP | Marketed | SURMOUNT-5 head-to-head -20.2% vs semaglutide -13.7% | Continued indication expansion |
| Semaglutide injectable/oral | Novo | GLP-1R | Marketed | STEP -14.9%; MACE/MASH/OSA labels | 7.2mg high-dose ramp |
| Oral Wegovy 25mg | Novo | GLP-1R oral | Launched 2026-01 | 1/3 of new prescriptions within 8 weeks of launch | Delivery of tenfold capacity expansion |
| Foundayo (orforglipron) | Lilly | Oral small molecule | Approved 2026-04 | ATTAIN-1 -12.4%@72wk | ATTAIN-2 (2027-08); filings in 40+ countries |
| CagriSema | Novo | GLP-1+amylin | Under FDA review | REDEFINE-1 -22.7%@68wk; REDEFINE-4 head-to-head -23%@84wk failed non-inferiority vs tirzepatide (2026-02) | FDA decision Q4 2026 |
| retatrutide | Lilly | Triple agonist | Phase III readout complete | TRIUMPH-1 -28.3%@80wk (45.3% of patients ≥30% weight loss) | Global filings Q4 2026–H1 2027 |
| MariTide | Amgen | Monthly injectable | Phase III | Ph II -20%@52wk, ~11% discontinuation | MARITIME-1 readout Q1 2027 |
| VK2735 | Viking | GLP-1/GIP | Phase III | -22% placebo-adjusted over 33 weeks maintenance, 90% weight loss retained | VANQUISH topline 2H 2027 |
| survodutide | BI/Zealand | GLP-1/GCG | Phase III readout complete | -16.6%; CVOT met primary endpoint at AHA 2026-11 | Global filings |
| Mazdutide | Innovent | GLP-1/GCG | Marketed in China | GLORY-1 6mg -14.0% (0.5% discontinuation); GLORY-2 9mg -18.6% | Head-to-head vs semaglutide data publication; volume ramp |
| HRS-9531 | Hengrui/Kailera | GLP-1/GIP | Global Phase III | Ph II -21.1%, 0 discontinuations due to adverse events | Global Phase III data 2027 |
| petrelintide/eloralintide | Roche/Zealand, Lilly | amylin | Phase III starting 2026 | Ph IIb ~-10.7% (tolerability narrative) | Phase III topline ~2029 |
Implications of the efficacy arms race: retatrutide pushes the ceiling to roughly 28–30% (8.1 percentage points above tirzepatide; weight-loss magnitude approaching bariatric surgery); if approved in 2027, it would compress the pricing space of all dual-agonist and amylin assets. CagriSema was filed at -22.7%, but the REDEFINE-4 head-to-head in 2026-02 failed to prove non-inferiority vs tirzepatide—"approval" and "comeback" have decoupled; Novo's premium-market defense now rests only on oral Wegovy and price. Third-generation differentiation (MariTide's monthly formulation, amylin tolerability, muscle preservation, maintenance therapy) is the only remaining path to breaking the duopoly narrative.
| Track | Pipeline/registered | Homogenization | Judgment |
|---|---|---|---|
| GLP-1R single-target injectables | 400+ clinical registrations combined (Novo 275 + Lilly 148, ClinicalTrials.gov); 20+ Chinese me-too players | 5/5 extremely crowded | Proven mechanism + Chinese patent expiry; terminal value converges toward generic economics |
| GLP-1/GIP dual | VK2735 (8 trials), HRS-9531, BGM0504 etc. | 4/5 crowded | Ceiling defined by tirzepatide; latecomers need oral or dosing differentiation |
| GLP-1/GCG dual | Mazdutide (marketed) + survodutide | 3/5 moderate | Differentiation in visceral fat/hepatic fat and CVOT labels |
| Triple agonists | retatrutide (33 trials) + HDM1005 | 2/5 sparse | Lilly nearly monopolizes the first tier |
| amylin class | CagriSema/petrelintide/eloralintide, three Phase III programs | 2/5 sparse | Most differentiated mechanism, but absolute efficacy trails multi-target agents |
| Oral small molecules | orforglipron 53 registrations, many followers | 4/5 crowded | Convenience dividend already cashed in by Lilly and Novo as first movers |
On 2024 global GLP-1 revenue, Novo held ~64% (~$29 billion: Ozempic $17.5bn + Wegovy $8.4bn + Rybelsus $3.3bn) vs. Lilly 36% (~$16.5 billion); on 2026Q3 US prescription volume, Lilly 63% vs. Novo 36.6% (per Lilly's earnings disclosure). Revenue scale: tirzepatide posted $16.02 billion in a single quarter of 2026Q3 (Mounjaro $10.72bn + Zepbound $5.30bn, ~$64.1bn annualized), already exceeding Novo's entire company quarterly revenue (DKK 79.2bn ≈ $11.9bn); Lilly guided 2026 full-year revenue at $91-92 billion, while Novo's 2026 guidance, after a November raise, is CER -2%~+2%.
Profits accrue almost entirely to the originator layer: the duopoly's combined GLP-1-related operating profit is ~$30 billion/year (based on ~40% adjusted EBIT margins; Lilly net margin 26.4% (Q3'26), Novo 33.1% (FY25)); CDMO is the second profit tier (WuXi TIDES gross margin 54%+, 2025 revenue +96%); delivery devices and generics/biosimilars are thin-margin. Over the next 2-3 years, four migrations proceed in parallel: ①Payer capture — US net price anchored down from $1,350/month list to $245-346 (68-82% discount), China entering reimbursement with roughly an 80% cut; ②Redistribution among players — Lilly systematically grabs share via efficacy + oral + capacity, Novo defends with oral Wegovy (Q3'26 sales DKK 5.39bn, +53% QoQ); ③Capacity-scarcity windfall reverts from CDMO to originators — WuXi TIDES growth guidance falls from +96% to ~+40%; ④From 2027, China's profit pool cedes from originators to the first-generic army and dilutes rapidly (historical reference: biosimilars cut prices ~15% one year post-launch and ~24% in five years, while Chinese originators have already cut prices ~48-80% in this cycle). BD and M&A are active: Pfizer completed the acquisition of Metsera for up to ~$10 billion (Novo's $6.5bn bid was rejected during the process); Roche-Zealand amylin licensing with $1.65bn upfront + up to $5.3bn in milestones; Hengrui licensed four assets to Kailera (Nasdaq IPO 2026-04); United Laboratories licensed its tri-agonist UBT251 to Novo — monetization of Chinese assets going overseas has become routine.
| Player | Positioning | Share/Scale | Light Metrics | One-Line Read |
|---|---|---|---|---|
| Lilly (LLY) | Three-pronged: tirzepatide + orforglipron + retatrutide | 63% US prescription share; tirzepatide ~$64.1bn annualized | 2026 guidance $91-92bn; gross margin 83.9%; PE (2026E) ~41× | The biggest structural beneficiary; only headwinds are declining net prices and a high valuation intolerant of any blemish |
| Novo Nordisk (NVO) | Full semaglutide lineup + oral Wegovy + CagriSema | 36.6% US prescription share; FY25 revenue DKK 309.1bn | Gross margin 81.0%; PE (TTM) ~12× | From leader to chaser: oral ramp is the cash-flow defense line; the CagriSema turnaround option has weakened after head-to-head failure |
| Amgen (AMGN) | MariTide monthly formulation | No GLP-1 revenue; Phase III readout 2027Q1 | FY25 revenue $36.75bn | A differentiated monthly formulation is a free option; the data decides three-player vs. duopoly |
| Viking (VKTX) | VK2735 injectable + oral | Clinical stage | No revenue | Best maintenance-phase data among challengers; 2027H2 is the M&A/licensing pricing point |
| Innovent Biologics (01801.HK) | Mazdutide (China's first dual-agonist weight-loss drug) | 2026E ~RMB 1.8 billion | H1'26 total revenue HK$8.62bn +44.8%; gross margin 85%; PE (TTM) 104× | Best domestic positioning, but must prove dual-agonist premium in a price war |
| Hengrui Pharmaceuticals (600276) | HRS-9531 global Phase III (Kailera) + oral pipeline | 9M26 revenue RMB 24.41bn +5.3% | PE (TTM) 35.9× (0-1% 10-year percentile) | Low valuation + overseas structure; the best risk-reward metabolic exposure in A-shares |
| Huadong Medicine (000963) | Liraglutide first-mover + oral HDM1002 positive China Phase III | 9M26 revenue RMB 33.02bn +1.1% | PE (TTM) 13.2× (lowest percentile range since listing) | Deep value + free oral option |
| United Laboratories (03933.HK) | Semaglutide generic filing + UBT251 licensed to Novo | 2026H1 revenue HK$6.17bn -18% | PB 0.74 (2% 3-year percentile) | Deeply discounted double option; core-business decline needs hedging |
| Jiuyuan Gene (02189.HK) | First semaglutide generic filing (2024-04) | N/A | N/A | Earliest first-generic positioning, but approval means a red ocean; the dividend window may be only 12-18 months |
| WuXi AppTec (603259) | TIDES peptide CDMO global tier one | TIDES 2025 revenue RMB 11.37bn +96% | 9M26 non-GAAP +73%; PE (TTM) 16.8× (market cap at 95% 5-year percentile) | The surest seller of shovels during capacity scarcity; slowing order growth and BIOSECURE are main headwinds |
A-shares have no GLP-1-specific sector index; use Shenwan Pharmaceutical & Biotech (801150.SI) as the anchor: PE 29.62× (24% percentile since 2014), PB 2.44× (5% percentile, 2026-11-13) — pharma overall remains historically cheap. But internal divergence is stark: manufacturing has been re-rated (WuXi's market cap at the 95% 5-year percentile, Asymchem PE 45× at the 88% 3-year percentile), while innovation remains at lows (Hengrui at the 0-1% 10-year percentile, Huadong in its lowest range since listing); overseas, Lilly trades at PE (2026E) ~41×, a fresh stage high, while Novo trades at ~12× at a deep discount. The same "upcycle" starts from completely different valuation points across segments — this directly determines the allocation conclusions in I8.
Tirzepatide entered the 2025 national reimbursement list under the T2DM indication (four strengths at RMB 324-936/vial, average cut ~80%); mazdutide (Xin'ermei) entered the 2026 list under T2DM (announced 2026-11-14) — weight loss/OSA indications were not included, and the commercial insurance innovative drug list (28 drugs) also contains no GLP-1 weight-loss product; the option monetization channel for the 402 million overweight/obese population currently rests only on the self-pay market. The price war started early: Novo's Wegovy in Sichuan procurement voluntarily cut prices ~48% (RMB 2,463 → 1,284/vial), while Mazdutide's e-commerce subsidized price is ~RMB 450/vial (-79% vs. official guidance). After the semaglutide patent expires 2026-03-20, data exclusivity (until 2027-04) is the last gate for first generics, after which 10+ filings will turn China into a cost market — benchmarking against this cycle's ~80% reimbursement cuts rather than insulin VBP's ~50% is the more prudent base-case assumption.
UK NICE TA1026 publicly funds tirzepatide for weight loss (BMI≥35 + comorbidity, discontinuation if <5% weight loss at 16 weeks, phased rollout); Germany's statutory insurance explicitly excludes weight-loss indications under §34 SGB V (fully self-paid); Japan restricts to BMI≥27 + comorbidities with stable public pricing. Net direction assessment: on volume, policy is a tailwind (expanding covered populations); on price, it is a persistent headwind (systematic downward shift of net-price midpoint) — policy is transforming the industry from a "high-margin scarce good" into "mass chronic-disease infrastructure."
| Scenario | Probability | Narrative | Industry Revenue Landing Point (2030) |
|---|---|---|---|
| Bear | 25% | Wider commercial-insurance clearing + GUARD enacted + Bridge not renewed + China's -80% price war fully generalized + CagriSema approved but undifferentiated | $95-110bn (GS path holds), profits concentrate toward Lilly's single pole |
| Base | 50% | Oral expansion + rising penetration offsets net-price decline; moving floor drifts lower slowly; Lilly holds the lead, Novo stabilizes cash flow, China sees volume up/price collapse, CDMO growth slows but no crash | $120-135bn (midpoint of this bridge: $131.6bn) |
| Bull | 25% | Retatrutide approval resets the ceiling + new indications like HFpEF/knee OA ramp + China commercial insurance covers weight loss + Bridge/BALANCE institutionalized | Above $150bn (toward JPM's $200bn) |
| Timing | Event | Directional Impact | Swing Factor |
|---|---|---|---|
| 2026-12-14 | Novo NNC0662-0419 (next-gen amylin) Phase II readout | Novo pipeline depth | D2 |
| 2026Q4 | CagriSema FDA decision (no public PDUFA) | Novo turnaround odds / duopoly balance | D2 |
| 2027-01-01 | Semaglutide IRA negotiated price of $274/month takes effect; GLOBE (Part B MFN) takes effect | US net-price midpoint shifts lower | D1 |
| 2027Q1 | MariTide MARITIME-1 Phase III readout | Monthly formulation success; three-player or not | D2 |
| 2027H1 | Retatrutide global filings | Efficacy ceiling reset | D2 |
| Mid-2027 | Whether CMS extends the GLP-1 Bridge / advances BALANCE | Medicare coverage duration | D1 |
| After 2027-04 | China semaglutide data exclusivity expires → first-generic approval window | Deepening China price war | D3 |
| 2027H2 | VK2735 VANQUISH topline; orforglipron ATTAIN-2 (2027-08) | Challenger data / oral T2DM expansion | D1/D2 |
| During 2027 | Tirzepatide ANDA PIV litigation (Hansoh + Sandoz) key milestones | Whether Lilly's 2036 cliff arrives early | D2 |
One-line takeaway: a bullish upcycle ≠ worth buying. China's semaglutide generic army and richly valued second-tier peptide capacity sit in the bottom-right — volume is growing, but the money doesn't go to them (10+ players bidding against ~80% cuts, device demand eroded by oral); Lilly sits top-right (pipeline + capacity + patents, a trinity); Novo sits upper-left (declining share but still hard cash flows and patent moats — a turnaround candidate, not a value trap); United Laboratories and the injection device chain sit bottom-left — avoid.
| Scenario | Biggest Beneficiaries | Biggest Losers |
|---|---|---|
| Bear | Lilly (monopolistic concentration, thickest cash flow); WuXi AppTec (existing backlog + relative outperformance) | Novo (turnaround thesis falsified + second net price decline); Chinese generic army and second-tier CDMOs (price war benchmark -80%) |
| Base | Lilly, WuXi AppTec, Hengrui (overseas expansion materializes), Innovent (first-mover volume growth) | Injection device chain, Jiuyuan and other pure generic positioning |
| Bull | Novo (10x oral capacity expansion materializes + CagriSema approval repair), Amgen (monthly formulation validated), Innovent (double boost from commercial insurance/overseas expansion) | Pure generics and second-tier CDMOs relatively underperform (innovation premium widens again) |
(For individual stocks of interest, dedicated profiles with price targets and in-depth company analysis can be prepared separately.)
① US commercial insurance coverage tightens faster than Medicare/self-pay expansion, keeping revenue penetration systematically below prescription penetration; ② GUARD/MFN legislation further breaks through the net price floor; ③ CagriSema approval delays or label restrictions, MariTide Phase III failure, intensifying divergence within the duopoly; ④ Post-2027-04 first-generic price war in China deeper than expected and spilling over into other emerging markets (generic costs only US$28–140/person·year); ⑤ Tail risk of litigation and prescribing hesitancy from the NAION safety label; ⑥ Tirzepatide ANDA settlement introducing authorized generics before 2031; ⑦ BIOSECURE expansion disrupting Chinese CDMO orders and the global peptide supply chain.